comparemela.com
Home
Live Updates
FDA Approves Glofitamab-gxbm to Treat Adults With Relapsed/Refractory DLBCL : comparemela.com
FDA Approves Glofitamab-gxbm to Treat Adults With Relapsed/Refractory DLBCL
Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Related Keywords
Sweden ,
United States ,
Copenhagen ,
Køavn ,
Denmark ,
Swedish ,
American ,
Krish Patel ,
Martin Hutchings ,
Genentech Columvi ,
Levi Garraway ,
Lymphoma Program ,
Global Product Development ,
Leukemia Lymphoma Society ,
Swedish Cancer Institute In Seattle ,
American Society Of Hematology ,
Genentech ,
Department Of Hematology ,
Copenhagen University Hospital ,
Swedish Cancer Institute ,
American Society ,
Accessed June ,
Dlbcl ,
Glofitamab ,
Fda Approval ,
comparemela.com © 2020. All Rights Reserved.